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OBJECTIVES This study was designed to investigate the prognostic value of cardiac troponin I (cTnI) in
viral or idiopathic pericarditis.
BACKGROUND Idiopathic acute pericarditis has been recently reported as a possible cause of nonischemic
release of cTnI. The prognostic value of this observation remains unknown.
METHODS We enrolled 118 consecutive cases (age 49.2  18.4 years; 61 men) within 24 h of symptoms
onset. A highly sensitive enzymoimmunofluorometric method was used to measure cTnI
(acute myocardial infarction [AMI] threshold was 1.5 ng/ml).
RESULTS A cTnI rise was detectable in 38 patients (32.2%). The following characteristics were more
frequently associated with a positive cTnI test: younger age (p  0.001), male gender (p 
0.007), ST-segment elevation (p  0.001), and pericardial effusion (p  0.007) at
presentation. An increase beyond AMI threshold was present in nine cases (7.6%), with an
associated creatine kinase-MB elevation, a release pattern similar to AMI, and echocardio-
graphic diffuse or localized abnormal left ventricular wall motion without detectable coronary
artery disease. After a mean follow-up of 24 months a similar rate of complications was found
in patients with a positive or a negative cTnI test (recurrent pericarditis: 18.4 vs. 18.8%;
constrictive pericarditis: 0 vs. 1.3%, for all p  NS; no cases of cardiac tamponade or residual
left ventricular dysfunction were detected).
CONCLUSIONS In viral or idiopathic acute pericarditis cTnI elevation is frequently observed and commonly
associated with young age, male gender, ST-segment elevation, and pericardial effusion at
presentation. cTnI increase is roughly related to the extent of myocardial inflammatory
involvement and, unlike acute coronary syndromes, is not a negative prognostic
marker. (J Am Coll Cardiol 2003;42:2144–8) © 2003 by the American College of
Cardiology Foundation
Troponins I and T are regulatory proteins that control the
calcium-mediated interaction of actin and myosin (1). The
cardiac forms of these proteins are products of specific genes
and therefore have the potential to be unique for the heart.
Studies performed with cardiac troponin I (cTnI), the
cardiac muscle isoform of troponin I, have failed to find any
cTnI outside of the heart at any stage of neonatal develop-
ment (2,3); moreover, an increase in cTnI circulating levels
is highly indicative of myocardium injury (2).
Cardiac troponin I has been extensively studied as a
diagnostic and prognostic marker in acute coronary syn-
dromes, and recent studies have demonstrated increased
circulating levels in conditions with myocardial injury dif-
ferent from coronary heart disease (4–6).
The inflammatory process of acute pericarditis may in-
volve the epicardium and cause myocardial damage, as
reflected by creatine kinase (CK)-MB enzyme release (7).
This damage may be also responsible for cTnI release in
patients with acute pericarditis, as recently reported (8,9).
The temporal pattern of this release is similar to that of an
acute myocardial infarction (AMI); however, the true prog-
nostic significance of cTnI remains unknown in this setting
(8,9).
The aim of this work is to investigate the clinical and
prognostic value of cTnI release in patients with viral or
idiopathic acute pericarditis.
METHODS
Patients. This study was performed with the approval of
the institutional review board and subjects gave informed
consent. From January 2000 to January 2002 we prospec-
tively studied all consecutive cases of acute pericarditis
admitted to the Emergency Department or our Cardiology
Department (including ambulatory and day hospital service)
within 24 h of symptom onset. Acute pericarditis was
diagnosed with at least two of the following criteria:
pericarditic chest pain, pericardial friction rub, and wide-
spread ST-segment elevation on the electrocardiogram
(ECG). A complete echocardiographic study was performed
in all patients using a Hewlett-Packard 2500 or 5500
machine (Palo Alto, California). Initial evaluation included
ECG, chest X-ray, and routine laboratory tests (blood cell
count, sedimentation rate, acute phase reactants, serum
urea, and creatinine) as well as antinuclear antibody titers,
rheumatoid factor, tuberculin skin test, human immunode-
ficiency virus serology, and, if the patient was febrile, blood
cultures. Appropriate studies were performed if initial eval-
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uation suggested a specific cause, such as tuberculosis or
malignancy. We did not routinely obtain viral studies,
because the yield is low and management is not altered by
viral serology results. In the future this approach may
change with the introduction into clinical practice of new
treatments for specific viral infections. Pericardiocentesis
was performed in patients with cardiac tamponade, sus-
pected purulent pericarditis, clinical activity, or effusion
persisting for more than one week after aspirin therapy.
Surgical drainage and pericardial biopsy were limited to
relapses of cardiac tamponade after pericardiocentesis or
cases with persistent illness for more than three weeks
without evident etiology. Institution of antituberculosis
therapy was performed if the diagnosis of tuberculous
pericarditis was established (10,11).
To avoid confounding effects of different secondary eti-
ologies with an unfavorable prognosis (such as tumor), only
viral or idiopathic acute pericarditis cases were included in
the study after exclusion of secondary causes (including
tumors, connective tissue disease, tuberculous pericarditis,
and other discernible etiologies).
Patients with viral or idiopathic acute pericarditis were
treated with aspirin (800 mg orally every 6 or 8 h for 7 to 10
days with gradual tapering over 2 to 3 weeks) and gastro-
protection with misoprostol (600 to 800 g daily) or
omeprazole (20 mg daily).
A clinical and echocardiographic follow-up was per-
formed at 48 to 72 h, 7 to 10 days, 1 month, 6 months, and
1 year and then yearly in noncomplicated cases.
cTnI and CK-MB assays. Venous blood for determina-
tion of cTnI, CK-MB fraction was collected on dry tubes
from an antecubital vein. The cTnI was measured using a
Dade Behring Flex reagent cartridge (Deerfield, Illinois),
based on a highly sensitive enzymoimmunofluorometric
method with a lowest measurable concentration of 0.04
ng/ml, reference interval: 0 to 0.1 ng/ml and an AMI
threshold: of 1.5 ng/ml). The CK-MB enzyme release was
measured using Dade Behring Flex reagent for CK-MB, an
immunoinhibition assay (lowest measurable concentration
of 1.0 U/l, reference interval 6 ng/ml). The cTnI and
CK-MB assays performances were according to the Euro-
pean Society of Cardiology and American College of
Cardiology consensus document (12). All patients had serial
cTnI measurements independently from the first assay result
to exclude a late cTnI rise.
An acute coronary syndrome was excluded as a possible
etiology for cTnI elevation. All patients with a cTnI assay
beyond AMI threshold underwent coronary angiography to
exclude coronary artery disease (CAD) or coronary artery
spasm by ergonovine test. Other patients with a positive
cTnI test below AMI threshold underwent functional tests
(exercise ECG or stress echocardiography) to exclude CAD.
Statistical analysis. Data were expressed as mean  SD.
Comparison between patient groups were performed using
unpaired t test for continuous variables and a chi-square
analysis for categorical variables. Correlations between cTnI
and CK-MB levels were calculated by Spearman correla-
tion. A p value of 0.05 was considered to show statistical
significance.
RESULTS
Patients. A total of 118 consecutive cases of viral or
idiopathic acute pericarditis (80.5% of all cases presenting
with acute pericarditis) were included within 24 h of
symptoms onset. Mean age was 49.2  18.4 with 61 men
(51.7%). Fever was present in 59 cases (50.0%), pericardial
friction rubs in 40 cases (33.8%), and ST-segment elevation
in 82 cases (69.5%), with a typical ECG evolution in 65
cases (55.1%). PR-segment depression was recorded in 90
cases (76.3%) and was associated with ST-segment eleva-
tion in 59 cases (50.0%). A pericardial effusion was detected
in 71 cases (60.2%); in all cases the effusion was small with
a good response to medical therapy. According to our study
protocol we did not perform pericardiocentesis or any
diagnostic work on pericardial fluid in these cases. Echo-
cardiographic diffuse or localized abnormal ventricular wall
motion was recorded in nine cases (7.6%).
cTnI and CK-MB values. A cTnI rise was detectable in
38 patients (32.2% of cases). The mean cTnI value was 1.02
 1.21 ng/ml (range 0.2 to 28.0 ng/ml).
The ST-segment elevation was observed in almost all
cases with a detectable cTnI (37/38; 97.4%). Sensitivity of
ST-segment elevation to detect important myocardial injury
(cTnI 1.5 ng/ml) was 88.9%, but its specificity was only
32.1%. This sensitivity was improved to 100% by concom-
itant PR-segment depression.
The following characteristics (Table 1) were more fre-
Abbreviations and Acronyms
AMI  acute myocardial infarction
CAD coronary artery disease
CK  creatine kinase
cTnI  cardiac troponin I
ECG electrocardiogram
Table 1. Clinical, Electrocardiographic, and Echocardiographic
Findings in Patients With Viral or Idiopathic Acute Pericarditis
With and Without Detectable cTnI
Serum cTnI






Age (yrs) 57.3  15.1 31.9  11.4 0.001
Male gender 34 (42.5) 27 (71.0) 0.007
Pericardial friction rub 29 (36.2) 11 (28.9) NS
ST-segment elevation 45 (56.2) 37 (97.4) 0.001
Pericardial effusion 48 (60.0) 33 (86.8) 0.007
Erythrocite sedimentation (mm) 34  30 38  28 NS
C-reactive protein (mg/ml) 70  50 80  40 NS
White blood count (103/ml) 11  4 12  3 NS
Mean  standard deviation or number of cases (percentage).
cTnI  cardiac troponin I.
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quently associated with a positive cTnI test: younger age
(31.9  11.4 years vs. 57.3  15.1 years, p  0.001), male
gender (71% vs. 42.5%, p  0.007), ST-segment elevation
(97.4% vs. 56.2%, p  0.001) and pericardial effusion at
presentation (86.8% vs. 60.0%, p  0.007). Among patients
with a positive cTnI test a mild increase of cTnI (0.4
ng/ml) was detected in 29 cases (group I: 24.6% of all)
without CK-MB elevation. An increase beyond AMI
threshold was present in nine cases with an associated
CK-MB elevation and echocardiographic diffuse or local-
ized abnormal left ventricular wall motion (group II: 7.6%
of all patient and 23.7% of positive cTnI cases; mean cTnI:
11.6  7.8 ng/ml: mean CK-MB peak 23.6  19.0 U/l).
There was a significant correlation between cTnI and
CK-MB values (r  0.60; p  0.05). In these cases CAD
was excluded by angiography and myopericarditis was diag-
nosed. In group II cTnI temporal pattern was similar to that
seen in AMI with levels detectable for five to six days,
whereas in group I the temporal pattern was shorter (2 to 3
days) (Fig. 1).
According to our study protocol initial routine treatment
was the same in all patients, and there were no differences in
treatment between patients with a positive or a negative
cTnI test. A mean follow-up of 24 months (range 8 to 30
months) was performed. A similar rate of complications
(Table 2) was found in patients with a positive or a negative
cTnI test (recurrent pericarditis: 18.4% vs. 18.7%; constric-
tive pericarditis: 0 vs. 1.3%, for all p  NS; no cases of
cardiac tamponade or residual left ventricular dysfunction
were detected). A complete regression of left ventricular
regional wall motion abnormalities was documented in all
patients in group II with recovery.
DISCUSSION
Major findings. Elevations of cTnI levels have been ob-
served across a spectrum of acute coronary syndromes
including Q-wave MI, non–Q-wave MI, and unstable
angina. At present, troponins are the primary biochemical
tests for the diagnosis of AMI (12). Moreover cTnI has
been extensively studied as a prognostic marker in acute
coronary syndromes: the prognostic value of elevated serum
troponins has been demonstrated in patients with unstable
angina and both non–Q-wave and Q-wave myocardial
infarction (13–15).
Several studies have also demonstrated increased circu-
lating levels of cTnI in conditions with myocardial injury
different from coronary heart disease, such as congestive
heart failure, myocarditis, and pulmonary embolism (4–6).
Recently increased serum levels of cTnI have been reported
in idiopathic acute pericarditis (8,9).
In the first report (8), a retrospective monocentric study,
69 hospitalized patients were included after review of the
emergency department and hospital databases. In this study
serum cTnI was detected on admission in 34 patients (49%
of cases) and was beyond the AMI threshold in 15 cases
(22%). The cTnI increase was seen almost only in patients
with ST-segment elevation. Patients with higher values of
cTnI were younger and had a recent infection.
In the second observational report (9), 14 patients with
idiopathic acute pericarditis were enrolled at admission to
the emergency department within 24 h of symptom onset.
The cTnI elevation was observed in 10 cases (71%). In
this study cTnI levels were detectable for a maximum of six
days and with a temporal pattern similar to that observed in
AMI. The prognostic value of this observation was not
investigated.
In these studies serum cTnI elevation was not related to
symptom intensity or disease severity, and the prognostic
significance of the observation was not investigated prospec-
tively.
To the present our study is the largest report of serum
cTnI elevation in viral or idiopathic acute pericarditis, and
the first prospective one to evaluate its clinical and prog-
nostic value. The cTnI was evaluated at admission within
24 h of symptom onset and later every 6 h for one day and
then daily. We observed an increase of serum cTnI in only
32.2% of cases, with a value that was above AMI threshold
(1.5 ng/ml) in 7.6% of cases. A positive cTnI test was
Figure 1. Temporal changes of cardiac troponin I (cTnI) in viral or
idiopathic acute pericarditis. In group II (solid line, squares) cTnI
temporal pattern was similar to that seen in acute myocardial infarction
with levels detectable for 5 to 6 days while in group I (dashed line, circles)
cTnI temporal pattern was shorter (2 to 3 days). Data are expressed as
means  standard deviations from 29 patients in group I and from nine
patients in group II.
Table 2. Complications and Clinical Events During a Mean
Follow-Up of 24 Months (Range 8 to 30 Months)
Serum cTnI






Recurrent pericarditis 15 (18.8%) 7 (18.4%) NS
Cardiac tamponade 0 0 NS




Congestive heart failure 0 0 NS
Dilated cardiomyopathy 0 0 NS
cTnI  cardiac troponin I.
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associated with younger age, male gender, ST-segment
elevation, and pericardial effusion at presentation (for all p
 0.01). Moreover, we observed that the highest values of
cTnI (1.5 ng/ml) were associated with CK-MB elevation
and echocardiographic wall motion abnormalities; in these
cases CAD was excluded by coronary angiography and
myopericarditis was diagnosed. The longer time period of
elevated cTnI levels in group II was probably the result of a
more severe myocardial involvement.
In our experience the entity of serum cTnI elevation is
roughly related to disease severity, probably reflecting the
extent of inflammatory and degenerative changes of the
superficial myocardium.
Moreover, related to the severity of the disease, we
observed two different temporal patterns of cTnI release.
The most frequent pattern of cTnI release was observed in
24.6% of all cases with a mild increase of serum cTnI (0.4
ng/ml) without CK-MB elevation lasting for 3 days (Fig.
1). Higher values of cTnI (1.5 ng/ml) were observed in
7.6% of all cases together with CK-MB elevation, echocar-
diographic wall motion abnormalities, and a prolonged
pattern similar to that observed in AMI (Fig. 1). Despite
different temporal patterns, we found a similar rate of
complications in patients with a positive (independently
from cTnI peak levels) or a negative cTnI test.
In comparison with previous studies we observed a less
frequent cTnI release in idiopathic acute pericarditis: only
32.2% of cases compared with 49% to 71% of reported
studies (8,9). These differences can be explained considering
different study design, setting, sample size and cTnI assays
(Table 3).
In the present study, 118 consecutive patients with viral
or idiopathic acute pericarditis were enrolled in a prospec-
tive study, including hospitalized patients and patients
treated on an ambulatory or day hospital basis. Hospitalized
patients are generally clinically more severe to require
hospitalization; thus, patient preselection cannot be ex-
cluded in previous studies and could be responsible for an
overrating of cases with a positive cTnI test.
Study limitations. If cTnI elevation reflects more extensive
acute myocardial inflammation and injury, then one might
expect that a positive value would carry prognostic signifi-
cance. However, the pathophysiologic process leading to
cTnI release in myopericarditis is distinctly different from
that in patients with acute coronary syndromes, and it is
uncertain whether a cTnI elevation carries the same prog-
nostic value. Acute pericarditis etiologies are diverse, and
prognosis may be related more to the underlying illness than
the presence or absence of troponin release (16). In this
study only viral or idiopathic cases of acute pericarditis were
studied.
It is generally known based on dated previous reports
(10,11) that idiopathic acute pericarditis can have a good
prognosis therefore it would seem unlikely that cTnI is able
to predict poor prognosis in patients with viral or idiopathic
acute pericarditis, however this hypothesis has not been
formally tested in a prospective study. Recent papers re-
ported cTnI release in patients with idiopathic acute peri-
carditis, sometimes with a temporal pattern similar to that
of an AMI, but the true prognostic significance of these
observations remain unknown in this setting (8,9). To the
present, even if it is a single-center observational study, this
report represents the largest series of patients with viral or
idiopathic acute pericarditis evaluated for markers of myo-
cardial injury.
Conclusions. The cTnI elevation is not rare in viral or
idiopathic acute pericarditis, but is less frequent than pre-
viously reported, and is probably the biochemical evidence
of myocardial inflammatory damage. It is associated with
young age, male gender, ST-segment elevation, and peri-
cardial effusion at presentation and is roughly related to the
disease severity, probably reflecting the extent of inflamma-
tory and degenerative changes of the superficial myocar-
dium, with the highest values generally observed during
myopericarditis. Unlike acute coronary syndromes, cTnI is
not a negative prognostic marker in viral or idiopathic acute
pericarditis.
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